Return-to-activity rates cited in published case series range from 55–85%, depending on injury severity and pre-treatment duration of symptoms. Acute tears (≤3 months) tend to show better outcomes than chronic tendinopathy (>1 year). In the absence of blinded controls, distinguishing spontaneous healing from therapy-induced improvement remains difficult; many athletes also undergo structured physiotherapy concurrently.
The tendon-injury cell-therapy landscape encompasses 22 completed trials and 1 actively recruiting study. Most involve placental MSC injections or exosome preparations administered directly into the tendon lesion under ultrasound guidance. Trial cohorts typically include both acute partial tears and chronic degenerative tendinopathy. Imaging outcomes (ultrasound, MRI) in small studies show improved fibre continuity and reduced fluid signal in approximately 50–70% of treated tendons. Functional metrics (strength, pain reduction, return-to-activity) vary by trial; some report 60–80% of athletes returning to sport within 6–12 months, though untreated controls are rarely present for comparison.
Am I a candidate? → · Tendon & Sports Injuries: full overview → · Tendon & Sports Injuries cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估